| GO web | GO term | GO Term Cat. |
|---|---|---|
| GO:0050918 | positive chemotaxis | BP |
| Literature link | GPT Summary | Evidence category | Disease type |
|---|---|---|---|
| 34542985 | This study investigated the role of glycoprotein non-metastatic melanoma protein B (GPNMB) as a biomarker for gestational diabetes mellitus (GDM). Serum GPNMB levels were measured using ELISA in GDM and normoglycemic pregnant women across different gestational stages. GPNMB levels were significantly higher in the GDM group at 5–12, 13–23, and 24–28 weeks, but not at 29–37 weeks of gestation. Overall, GPNMB levels in the GDM group were markedly elevated compared to the control group and showed positive correlations with fasting plasma glucose (r = 0.562) and HbA1c (r = 0.652, both p < 0.0001). ROC curve analysis revealed that GPNMB levels at 13–23 weeks were effective in predicting GDM after 24 weeks, with a sensitivity of 80% and specificity of 72% at a cutoff value of 2.46 μg/L. These findings suggest that elevated GPNMB levels during early-to-mid pregnancy are an independent risk factor for GDM and may serve as a target for early intervention to prevent the progression of GDM. |
Risk factor |
GDM |
| 32694855 | Metabolism in mammals is regulated by the complex interplay between different organs, and fatty acid synthesis is a key process that is modulated differently in white adipose tissue (WAT) and the liver. In this study, we identify glycoprotein non-metastatic melanoma protein B (Gpnmb) as a critical factor involved in liver-WAT cross-talk and lipogenesis regulation. We show that inhibition of the hepatic sterol regulatory element-binding protein (SREBP) pathway leads to increased transcription of Gpnmb and promotes its processing into a secreted form. Gpnmb acts to stimulate lipogenesis in WAT, exacerbating diet-induced obesity and insulin resistance. Human data also reveal that Gpnmb is tightly associated with body mass index and serves as a strong risk factor for obesity. Importantly, inhibiting Gpnmb using a neutralizing antibody or through liver-specific knockdown improves metabolic parameters, including reduced weight gain and enhanced insulin sensitivity, likely through promoting the beiging of WAT. These findings highlight Gpnmb as a liver-secreted factor that regulates lipogenesis in WAT and suggest that targeting Gpnmb could offer a potential therapeutic strategy for managing obesity and diabetes. | Mechanism | Insulin resistance |
Expressing in serum:
↑
RF's name
GPNMB
RF's type
mRNA